High pre-procedural plasma ADMA levels (>0.62 microM) significantly increased the risk of major adverse cardiovascular events after PCI compared to low levels (RR 5.3; 95% CI 2.2-12.9; P<0.001).
Cohort (n=153)
Does pre-procedural plasma ADMA level predict adverse cardiovascular events in patients with stable angina undergoing PCI?
Elevated pre-procedural plasma ADMA levels are strongly associated with an increased risk of adverse cardiovascular events following PCI in patients with stable angina, offering a potential tool for risk stratification.
Estimación del efecto: RR 5.3 (95% CI 2.2-12.9)
Tasa de eventos absoluta: 54.9% vs 11.8%
valor p: p=<0.001
AIMS: We investigated the predictive value of plasma concentration of asymmetrical dimethylarginine (ADMA) on clinical outcome in patients undergoing percutaneous coronary intervention (PCI). METHODS AND RESULTS: One-hundred and fifty-three consecutive patients with stable angina and undergoing PCI were prospectively enrolled for clinical follow-up. Plasma ADMA levels were determined before procedure by high performance liquid chromatography. The major adverse cardiovascular events included cardiovascular death, myocardial infarction, and repeat revascularization of target vessels. Patients were grouped into tertiles according to their plasma ADMA levels. Over a follow-up period of 16 months (median), cardiovascular events occurred in 6 patients of tertile I (0.62microM), P<0.001. By multivariate analysis, tertiles of ADMA levels were independently associated with a higher risk of adverse cardiovascular events after PCI (relative risk: tertile II vs I: 3.0 1.2-7.7, P=0.022; tertile III vs I: 5.3 2.2-12.9, P<0.001). Moreover, plasma ADMA level in the highest tertile also appeared as a significant risk factor of subsequent death and non-fatal myocardial infarction after PCI (tertile III vs I, P=0.04). CONCLUSION: Pre-procedural plasma ADMA levels may independently predict subsequent adverse cardiovascular events in patients undergoing PCI. Measurement of plasma ADMA levels could provide a rationale for risk stratification of patients by measuring ADMA levels before intervention.
Tse-Min Lu (Mon,) conducted a cohort in Stable angina undergoing percutaneous coronary intervention (n=153). High plasma asymmetrical dimethylarginine (ADMA) levels (>0.62 microM) vs. Low plasma ADMA levels (<0.50 microM) was evaluated on Major adverse cardiovascular events (cardiovascular death, myocardial infarction, and repeat revascularization of target vessels) (RR 5.3, 95% CI 2.2-12.9, p=<0.001). High pre-procedural plasma ADMA levels (>0.62 microM) significantly increased the risk of major adverse cardiovascular events after PCI compared to low levels (RR 5.3; 95% CI 2.2-12.9; P<0.001).